Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Gastrointestinal Stromal Tumors 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Myeloproliferative Disorders 1Melanoma 1Digestive System Neoplasms 1Congenital Bone Marrow Failure Syndromes 1Burkitt Lymphoma 1Blast Crisis 1

Interventions

Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Congenital Bone Marrow Failure Syndromes × Imatinib Mesylate × 30 days × Clear all
NCT06090669 2026-06-03

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

National Institutes of Health Clinical Center (CC)

Phase 1 Recruiting
75 enrolled
Classical hematology

Congenital Bone Marrow Failure Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡